Liposomal adjuvant compositions for human papillomavirus vaccines
The combination of HPV VLPs with a liposomal adjuvant comprising GLA and QS-21 addresses the immunogenicity challenge of current HPV vaccines, enhancing immune responses and broadening protection against multiple HPV strains.
WO2026128401A1 Publication Date: 2026-06-18MERCK SHARP & DOHME LLC
Patent Information
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- MERCK SHARP & DOHME LLC
- Filing Date
- 2025-12-09
- Publication Date
- 2026-06-18
AI Technical Summary
⚠Technical Problem
Current HPV vaccines rely on aluminum-containing adjuvants that may not provide sufficient immunogenicity for higher valency vaccines, necessitating the development of alternative adjuvants to enhance immune responses.
⚗Method used
A composition comprising virus-like particles (VLPs) of HPV types 6, 11, 16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 55, 56, 58, 59, 66, 68, 69, 70, 73, and 82, combined with a liposomal adjuvant containing glucopyranosyl lipid A (GLA) and QS-21, optionally with aluminum adjuvant, to increase immunogenicity.
🎯Benefits of technology
The liposomal adjuvant composition significantly enhances the immune response to HPV VLPs, providing improved protection against a broader range of HPV strains with reduced number of healthcare visits and social stigma.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure 1 Figure 2
Abstract
The present disclosure provides a vaccine composition that includes, among other things, HPV virus-like particles (VLPs) of at least one type of human papillomavirus (HPV) selected from the group consisting of HPV types: 6, 11, 16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 55, 56, 58, 59, 66, 68, 73, and 82 and a liposomal adjuvant, and methods of inducing an immune response to HPV or methods of preventing infection of or reducing the likelihood of infection by HPV using the compositions.
Need to check novelty before this filing date? Find Prior Art